References
[1]. Chen YP, Chan ATC, Le QT, et al., Nasopharyngeal carcinoma. Lancet. 2019; 394(10192):64–80.
[2]. Li Y, Xu T, Qian W, et al. Radiation-induced nasopharyngeal ulcers after intensity modulated radiotherapy in primary nasopharyngeal carcinoma patients: a dose-volume-outcome analysis. Oral Oncol. 2018; 84:1-6.
[3].Wang FZ,Sun QQ, Jiang CE, et al.Additional induction chemotherapy to concurrent chemotherapy and intensity-modulated radiotherapy with or without nimotuzumab in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis.Journal of Cancer.2018; 9(3): 594-603.
[4]. Zhang XX, Ma L, Wang JL, et al. Management of oral mucositis in patients with head and neck cancer receiving chemoradiotherapy and/or molecular targeted therapy. Chin J Otorhinolaryngol Head Neck Surg. 2011; 46(6):505-508.
[5]. Du L, Zhang XX, Ma L, et al. Clinical study of nasopharyngeal carcinoma treated by helical tomotherapy in China: 5-year outcomes. Biomed Res Int. 2014; 980767.
[6]. Zheng L, Yan S, Yan D, et al. Fatal bleeding in a nasopharyngeal carcinoma patient after concurrent chemoradiation plus cetuximab: a case report. Onco Targets Ther. 2013; 6:703-706.
[7]. Zhang X, Wang J, Wu W, et al. Efficacy and safety of combined radiotherapy with EGFR inhibitors and chemotherapy for laryngeal organ preservation in patients with locally advanced hypopharyngeal carcinomas. Curr Cancer Drug Targets. 2014; 14(6):589-598.
[8]. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341-1346.
[9]. Yousem DM, Hatabu H, Hurst RW, et al. Carotid artery invasion by head and neck masses: prediction with MR imaging. Radiology. 1995; 195(3):715–720.
[10]. Wang ZQ, Mei Q, Li JB, et al. The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis. BMC Cancer. 2019; 19(1):1122.
[11]. Slevin F, Pan S, Mistry H, et al. A multicentre UK study of outcomes of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy ± chemotherapy. Clin Oncol (R Coll Radiol). 2020; 32(4):238-249.
[12]. Shen C, Lu JJ, Gu Y, et al. Prognostic impact of primary tumor volume in patients with nasopharyngeal carcinoma treated by definitive radiation therapy. Laryngoscope. 2008; 118(7):1206-1210.
[13]. Wu RK, Chen ZQ, Chen YL, et al. Risk factors, signs and prevention of massive bleeding in patients with nasopharyngeal carcinoma after radiotherapy. Internal Medicine. 2017; 12(3):392-394.(in China)
[14]. Yamazaki H,  Ogita M,  Himei K, et al. Carotid blowout syndrome in pharyngeal cancer patients treated by hypofractionated stereotactic re-irradiation using CyberKnife: a multi-institutional matched-cohort analysis. Radiother Oncol. 2015; 115(1):67-71.
[15]. Cheng KY, Lee KW, Chiang FY, et al. Rupture of radiation-induced internal carotid artery pseudoaneurysm in a patient with nasopharyngeal carcinoma–spontaneous occlusion of carotid artery due to long-term embolizing performance. Head Neck. 2008; 30(8):1132-1135.
[16]. Zheng LY, Yan SX, Yan DF, et al. Fatal bleeding in a nasopharyngeal carcinoma patient after concurrent chemoradiation plus cetuximab: a case report. Onco Targets Ther. 2013; 6:703–706.
[17]. Teo PM, Leung SF, Lee WY, et al. Intracavitary brachytherapy significantly enhances local control of early T-stage nasopharyngeal carcinoma: the existence of a dose-tumor-control relationship above conventional tumoricidal dose. Int J Radiat Oncol Biol Phys. 2000; 46(2):445-458.
[18]. Dionisi F, Fiorica F, D’Angelo E, et al. Organs at risk’s tolerance and dose limits for head and neck cancer re-irradiation: a literature review. Oral Oncol. 2019; 98:35–47.
[19]. Du L, Zhang XX, Feng LC, et al. Treatment of nasopharyngeal carcinoma using simultaneous modulated accelerated radiation therapy via helical tomotherapy: a phase II study. Radiol Oncol. 2016; 50(2):218-225.
[20]. Liu WS, Hsin CH, Chou YH, et al. Long-term results of intensity-modulated radiotherapy concomitant with chemotherapy for hypopharyngeal carcinoma aimed at laryngeal preservation. BMC Cancer. 2010; 10:102.
[21]. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354(6):567-578.
[22]. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010; 11(1):21-28.
[23]. Caudell JJ, Sawrie SM, Spencer SA, et al. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys. 2008; 71(3):676-681.
[24]. Ramakrishnan MS, Eswaraiah A, Crombet T, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. 2009; 1(1):41-48.
[25]. Diaz Miqueli A,  Rolff J,  Lemm M, et al. Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Br J Cancer. 2009; 100(6):950-958.